The synergy was largely blocked when Pdlim2 was genetically deleted from lung cancer cells (ΔSPC; Figure 6B and C), suggesting an important role of PDLIM2 in the combination therapy of chemotherapeutic drugs and anti-PD-1. Here, PDLIM2 is linked to lung carcinoma.